ScripsAmerica's Pharmaceutical Joint Venture Generates Over $116,000 in Revenue for November

TYSONS CORNER, Va., Dec. 18, 2013 (GLOBE NEWSWIRE) -- ScripsAmerica Inc. (OTCBB:SCRC), today announced that the Company has received and processed $116,987 in orders during November from its recent pharmaceutical distribution joint venture ("JV").

The JV has generated $246,781 in revenue for October and November as a result of ScripsAmerica providing independent pharmacies with wholesale prescription drugs. October and November's combined sales of over $245,000 keep ScripsAmerica on a run rate of over $1.4 million solely for this joint venture.

"November proved to be a very strong month in sales for our joint venture even with the Thanksgiving holiday, therefore keeping pace with previous months. Our run rate continues to be in the $1.5 million range and we expect to increase this rate as our partner continues its growth in the industry. We fully expect that wholesale pharmaceutical distribution to independent pharmacies will remain an area of steady growth for ScripsAmerica and our shareholder value throughout 2014," stated CEO of ScripsAmerica, Bob Schneiderman.

About ScripsAmerica, Inc.

ScripsAmerica, Inc. is a supplier of prescription, OTC and nutraceutical drugs, delivering pharmaceutical products to a wide range of end users across the health care industry. End users include retail pharmacies, hospitals, long-term care facilities and government and home care agencies. For more information, visit

Safe Harbor Statement

This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: 888-959-7095Source:ScripsAmerica, Inc.